Opendata, web and dolomites

iReceptor Plus SIGNED

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "iReceptor Plus" data sheet

The following table provides information about the project.

Coordinator
BAR ILAN UNIVERSITY 

Organization address
address: BAR ILAN UNIVERSITY CAMPUS
city: RAMAT GAN
postcode: 52900
website: www.biu.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 8˙505˙675 €
 EC max contribution 7˙856˙925 € (92%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BAR ILAN UNIVERSITY IL (RAMAT GAN) coordinator 975˙750.00
2    INESC TEC - INSTITUTO DE ENGENHARIADE SISTEMAS E COMPUTADORES, TECNOLOGIA E CIENCIA PT (PORTO) participant 877˙292.00
3    THE UNIVERSITY OF TEXAS SYSTEM US (AUSTIN) participant 679˙800.00
4    DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG DE (HEIDELBERG) participant 649˙750.00
5    SORBONNE UNIVERSITE FR (PARIS) participant 647˙000.00
6    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 556˙875.00
7    ASCORA GMBH DE (GANDERKESEE) participant 508˙750.00
8    UNIVERSITY OF HAIFA IL (HAIFA) participant 499˙375.00
9    INTERTEAM LTD IL (JERUSALEM) participant 400˙707.00
10    INFINIDAT LTD IL (HERZILIYA) participant 386˙750.00
11    UNIVERSITETET I OSLO NO (OSLO) participant 360˙000.00
12    MITMYNID LDA PT (AMARANTE) participant 301˙250.00
13    ACONDICIONAMIENTO TARRASENSE ASSOCIACION ES (TERRASSA) participant 280˙625.00
14    TIME.LEX BE (BRUSSEL) participant 265˙000.00
15    CLALIT HEALTH SERVICES IL (TEL AVIV) participant 167˙500.00
16    10X GENOMICS, INC. US (PLEASANTON) participant 150˙250.00
17    MEDGENOME INC US (FOSTER CITY) participant 150˙250.00
18    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 0.00
19    Simon Fraser University CA (BURNABY) participant 0.00
20    THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO CA (TORONTO) participant 0.00

Map

 Project objective

Background: Many cutting-edge therapies rely on manipulating the adaptive immune system, which has evolved a vast diversity (repertoire) of immune receptors to recognize and remove pathogens and cancer cells. The sequence-data sets characterizing this Adaptive Immune Receptor Repertoire (i.e., AIRR-seq data) have the potential to revolutionize vaccine research and the development of therapies against autoimmune diseases and cancer; however, AIRR-seq data are typically stored and curated by individual labs, using a variety of tools and technologies. Sharing these data in a common way across disease studies, labs, and institutions around the world will improve our ability to recognize patterns in basic research and clinical trials, and increase our confidence in these patterns. The existing iReceptor Platform uses community-developed standards to facilitate sharing of AIRR-seq data by enabling queries across a system of distributed data repositories.

Project: The iReceptor Plus consortium of researchers from Europe and Canada will address several key challenges to optimally sharing AIRR-seq data among public and industrial partners: protecting patient privacy and the intellectual property of partners, performing complex analyses on data brought together from many sources, and expanding the size and number of repositories that can be integrated in the network.

Impact: The iReceptor Plus project will facilitate sharing of AIRR-seq data among multiple institutions, including biopharmaceutical companies and researchers working with human confidential data, across multiple diseases, treatments and populations. This will lead to a better understanding of the causes of infectious and autoimmune diseases and cancer, which can lead to early detection and suggest novel therapies. These improvements will reduce the social and economic burden of these diseases, advance Europe and Canada’s leadership role in immunotherapy, and contribute to improved patient care worldwide

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IRECEPTOR PLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IRECEPTOR PLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

Instand-NGS4P (2020)

Integrated and standardized NGS workflows for Personalised therapy

Read More  

EUCAN-Connect (2019)

A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized health

Read More  

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More